Preview of the American Diabetes Association (ADA) 2026 Medical Meeting

Research evidence excerpt

Preview of the American Diabetes Association (ADA) 2026 Medical Meeting

Preview of the American Diabetes Association (ADA) 2026 Medical

Meeting

Notable News Ahead of ADA

DXCM: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues

Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 (6/4; see

full press release here):

• Highly anticipated presentation of results from the CONNECT randomized control trial will be

presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT.

• Early access launch of a completely reimagined Stelo app will likely define a new era of glucose

tracking for all people not on insulin seeking better health.

• Acquisition of Nutrisense should strengthen Dexcom’s ability to provide personalized nutrition

education and coaching to improve diabetes management and help further establish CGM as

an effective tool for preventative care.

PODD: Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod Simplifies

Diabetes Management and Delivers Strong Clinical Outcomes at ADA 2026 (6/4; see full press

release here):

• Presentations will feature next generation Omnipod innovations designed to reduce user

effort, new algorithm data, and clinical evidence demonstrating improved time in range.

• Insulet-led sessions will highlight how patient-centered design and strong clinical performance

is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes

PODD: Insulet Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands

Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor (6/3; see full press release here):

• Enhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps